Bone turnover markers and bone mineral density in patients with type 2 diabetes

Aysen Akalın; Göknur Yorulmaz; İ. Özkan Alataş; Kevser Onbaşı; Fatma Belgin Efe

Makale detayları

Bone turnover markers and bone mineral density in patients with type 2 diabetes

Yazarlar:

Aysen Akalın | Göknur Yorulmaz | İ. Özkan Alataş | Kevser Onbaşı | Fatma Belgin Efe

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Endocrinology

Dergi:

The European Research Journal Vol.9 Issue 2, pp.301-308

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282993

pISSN:

2149-3189

Anahtar kelimeler:

Özet:

 Background: This study was designed in order to evaluate bone and mineral metabolism in type 2 diabetic patients and its relationship with bone mineral density and diabetic microvascular complications. Methods: Forty two type 2 diabetic patients and 23 healthy cases were included in the study. Serum osteocalcin, procollagen type 1  C peptide PICP, total and bone specific alkaline phosphatase bone ALP, urinary deoxypyridinoline free DPD, parathormone PTH, serum and urinary calcium and phosphorus levels were measured. Bone mineral densities of all subjects were studied in lumbar vertebra and femur region using dual X-ray absorptiometry DXA. Results: Serum osteocalcin and bone ALP levels of the diabetics were found to be significantly lower and total alkaline phosphatase and calcium levels were higher in diabetic patients compared to healthy controls, but PICP and free DPD levels were not different between these two groups. There was a positive correlation between PTH levels and urinary DPD excretion. Among diabetics, serum osteocalcin levels increased with the impairment of renal functions. Bone mineral densities were lower in diabetics with worse renal functions. Conclusion: Bone turnover is slow in type 2 diabetes and there is no prominent bone loss related to this condition. PTH is an important factor determining the rate of bone resorption in diabetics. Renal functional impairment is the most important factor affecting the bone mass in type 2 diabetic patients.

 Background: This study was designed in order to evaluate bone and mineral metabolism in type 2 diabetic patients and its relationship with bone mineral density and diabetic microvascular complications. Methods: Forty two type 2 diabetic patients and 23 healthy cases were included in the study. Serum osteocalcin, procollagen type 1  C peptide PICP, total and bone specific alkaline phosphatase bone ALP, urinary deoxypyridinoline free DPD, parathormone PTH, serum and urinary calcium and phosphorus levels were measured. Bone mineral densities of all subjects were studied in lumbar vertebra and femur region using dual X-ray absorptiometry DXA. Results: Serum osteocalcin and bone ALP levels of the diabetics were found to be significantly lower and total alkaline phosphatase and calcium levels were higher in diabetic patients compared to healthy controls, but PICP and free DPD levels were not different between these two groups. There was a positive correlation between PTH levels and urinary DPD excretion. Among diabetics, serum osteocalcin levels increased with the impairment of renal functions. Bone mineral densities were lower in diabetics with worse renal functions. Conclusion: Bone turnover is slow in type 2 diabetes and there is no prominent bone loss related to this condition. PTH is an important factor determining the rate of bone resorption in diabetics. Renal functional impairment is the most important factor affecting the bone mass in type 2 diabetic patients.

 Background: This study was designed in order to evaluate bone and mineral metabolism in type 2 diabetic patients and its relationship with bone mineral density and diabetic microvascular complications. Methods: Forty two type 2 diabetic patients and 23 healthy cases were included in the study. Serum osteocalcin, procollagen type 1  C peptide PICP, total and bone specific alkaline phosphatase bone ALP, urinary deoxypyridinoline free DPD, parathormone PTH, serum and urinary calcium and phosphorus levels were measured. Bone mineral densities of all subjects were studied in lumbar vertebra and femur region using dual X-ray absorptiometry DXA. Results: Serum osteocalcin and bone ALP levels of the diabetics were found to be significantly lower and total alkaline phosphatase and calcium levels were higher in diabetic patients compared to healthy controls, but PICP and free DPD levels were not different between these two groups. There was a positive correlation between PTH levels and urinary DPD excretion. Among diabetics, serum osteocalcin levels increased with the impairment of renal functions. Bone mineral densities were lower in diabetics with worse renal functions. Conclusion: Bone turnover is slow in type 2 diabetes and there is no prominent bone loss related to this condition. PTH is an important factor determining the rate of bone resorption in diabetics. Renal functional impairment is the most important factor affecting the bone mass in type 2 diabetic patients.

 Background: This study was designed in order to evaluate bone and mineral metabolism in type 2 diabetic patients and its relationship with bone mineral density and diabetic microvascular complications. Methods: Forty two type 2 diabetic patients and 23 healthy cases were included in the study. Serum osteocalcin, procollagen type 1  C peptide PICP, total and bone specific alkaline phosphatase bone ALP, urinary deoxypyridinoline free DPD, parathormone PTH, serum and urinary calcium and phosphorus levels were measured. Bone mineral densities of all subjects were studied in lumbar vertebra and femur region using dual X-ray absorptiometry DXA. Results: Serum osteocalcin and bone ALP levels of the diabetics were found to be significantly lower and total alkaline phosphatase and calcium levels were higher in diabetic patients compared to healthy controls, but PICP and free DPD levels were not different between these two groups. There was a positive correlation between PTH levels and urinary DPD excretion. Among diabetics, serum osteocalcin levels increased with the impairment of renal functions. Bone mineral densities were lower in diabetics with worse renal functions. Conclusion: Bone turnover is slow in type 2 diabetes and there is no prominent bone loss related to this condition. PTH is an important factor determining the rate of bone resorption in diabetics. Renal functional impairment is the most important factor affecting the bone mass in type 2 diabetic patients.

Makale detayları

Bone turnover markers and bone mineral density in patients with type 2 diabetes

Yazarlar:

Aysen Akalın | Göknur Yorulmaz | İ. Özkan Alataş | Kevser Onbaşı | Fatma Belgin Efe

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Endocrinology

Dergi:

The European Research Journal Vol.9 Issue 2, pp.301-308

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282993

pISSN:

2149-3189

diabetes

bone mineral density

bone turnover

diabetic complications

Sayı

Makale detayları

Bone turnover markers and bone mineral density in patients with type 2 diabetes

Yazarlar: Aysen Akalın | Göknur Yorulmaz | İ. Özkan Alataş | Kevser Onbaşı | Fatma Belgin Efe

Yayıncı: Prusa Medical Publishing

Ana Başlıklar: Endocrinology

Dergi: The European Research Journal Vol.9 Issue 2, pp.301-308

Belge Tipi: Makale

Yayın Tarihi: 4/2023

Belge Dili: İngilizce

Document ID (Org No.): 2001282993

pISSN: 2149-3189

diabetes

bone mineral density

bone turnover

diabetic complications

Sayı

Yazarlar:

Aysen Akalın | Göknur Yorulmaz | İ. Özkan Alataş | Kevser Onbaşı | Fatma Belgin Efe

Yayıncı:

Prusa Medical Publishing

Ana Başlıklar:

Endocrinology

Dergi:

The European Research Journal Vol.9 Issue 2, pp.301-308

Belge Tipi:

Makale

Yayın Tarihi:

4/2023

Belge Dili:

İngilizce

Document ID (Org No.):

2001282993

pISSN:

2149-3189